SCHEMBL23588138

SCHEMBL23588138

CCOP(=O)(OCC)C(Cc1nc(-c2ccc(S(F)(F)(F)(F)F)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.37
MITF O75030 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
TSHR P16473 5/20 0.36
CYP1A2 P05177 3/20 0.36
CYP2C19 P33261 3/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 4/20 0.36
MAPK1 P28482 2/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
KLF5 Q13887 1/20 0.35
MAPT P10636 2/20 0.35
HPGD P15428 1/20 0.35
CYP2C9 P11712 2/20 0.35
CYP2D6 P10635 1/20 0.35
HTT P42858 1/20 0.35
GPR119 Q8TDV5 2/20 0.35
SIRT2 Q8IXJ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25804401 0.88 TSHR (0.47) TP53TSHRCYP1A2CYP2C19RAB9A
SCHEMBL25807564 0.88 TP53 (0.39) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23588293 0.88 HTT (0.40) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23588294 0.88 TP53 (0.39) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23578576 0.86 RAB9A (0.40) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23578190 0.85 PDE2A (0.30)
SCHEMBL25807039 0.85 RAB9A (0.39) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23588176 0.85 S1PR4 (0.40) TP53MITFNCOA3TSHRCYP1A2
SCHEMBL23588079 0.84 ACACB (0.46) TP53MITFNCOA3TSHRRAB9A
SCHEMBL25804667 0.84 SPHK1 (0.43) TP53MITFNCOA3TSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 US disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 TP53 2221/4885MITF 4809/4885NCOA3 1375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.